Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The two organizations will provide multi-modal learning experiences, opportunities to work with peers, and more.

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Many companies and investors believe that AI has to potential to reshape various elements of the pharma industry. Two ...